ORAL ADMINISTRATION OF ANTISIAN CONJUGATES TARGETING PCSK9
MA61691B2Active Publication Date: 2026-06-30CIVI BIOPHARMA INC
Patent Information
- Application Number
- MA61691
- Authority / Receiving Office
- MA · MA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-12-10
- Filing Date
- 2023-07-07
- Publication Date
- 2026-06-30
- Estimated Expiration
- 2043-07-07
Abstract
The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Method of treating cancer
WO2014046983A1
Antisense oligomers and conjugates targeting PCSK9
WO2014207232A1